We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B Turnover 24.14%
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+46.69%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.05B
AUM Growth
+$352M
Cap. Flow
-$16.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
43.96%
Holding
116
New
16
Increased
40
Reduced
31
Closed
12
Avg Time Held
2.7 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
1.8 years

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$31.1M
2
AVLN icon
Avalyn Pharma
AVLN
+$19.1M
3
PBLS
Parabilis Medicines Inc
PBLS
+$16M
4
COAG icon
Hemab Therapeutics
COAG
+$15.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.7M
2
ACLX icon
Arcellx
ACLX
+$19.5M
3
ELVN icon
Enliven Therapeutics
ELVN
+$15.4M
4
RVMD icon
Revolution Medicines
RVMD
+$15.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GKOS icon
101
Glaukos
GKOS
$9.77B
$664K 0.03%
+4,750
New +$601K
2026 Q2
0 quarters
JSPR icon
102
Jasper Therapeutics
JSPR
$17.7M
$463K 0.02%
1,100,726
– –
2024 Q1
9 quarters
BCRX icon
103
BioCryst Pharmaceuticals
BCRX
$2.05B
$221K 0.01%
22,124
+9,524
+76% +$86.1K
2026 Q1
1 quarter
MLTX icon
104
MoonLake Immunotherapeutics
MLTX
$873M
$208K 0.01%
10,696
-51,004
-83% -$925K
2025 Q3
3 quarters
ACHC icon
105
Acadia Healthcare
ACHC
$2.89B
– –
-75,500
Closed -$1.77M –
ACLX icon
106
DELISTED
Arcellx
ACLX
– –
-169,859
Closed -$19.5M –
APLS icon
107
DELISTED
Apellis Pharmaceuticals
APLS
– –
-162,750
Closed -$6.55M –
CNTA
108
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-351,828
Closed -$14M –
EW icon
109
Edwards Lifesciences
EW
$50.8B
– –
-28,900
Closed -$2.31M –
FOLD icon
110
DELISTED
Amicus Therapeutics
FOLD
– –
-21,062
Closed -$305K –
GOSS icon
111
Gossamer Bio
GOSS
$54.4M
– –
-20,119
Closed -$529K –
JAZZ icon
112
Jazz Pharmaceuticals
JAZZ
$13.9B
– –
-5,750
Closed -$1.09M –
REGN icon
113
Regeneron Pharmaceuticals
REGN
$82B
– –
-10,100
Closed -$7.8M –
SLNO icon
114
DELISTED
Soleno Therapeutics
SLNO
– –
-257,253
Closed -$8.61M –
TERN icon
115
DELISTED
Terns Pharmaceuticals
TERN
– –
-113,748
Closed -$6M –
XBI icon
116
State Street SPDR S&P Biotech ETF
XBI
$9.9B
– –
-30,000
Closed -$3.83M –
1 2 3 4
5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rock Springs Capital Management held 116 positions worth $2.05B, up 21% from $1.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rock Springs Capital Management's Q2 2026 filing shows 16 new, 40 increased, 31 reduced and 12 closed positions. Its largest new stake was Avalyn Pharma: 662,918 shares worth $21.8M. The largest sale was argenx, an estimated $37.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Rock Springs Capital Management's largest Q2 2026 buy was Avalyn Pharma: 662,918 shares worth $21.8M.
  • Rock Springs Capital Management added most to Travere Therapeutics in Q2 2026, an estimated $31.1M increase.
  • Rock Springs Capital Management's biggest Q2 2026 reduction was argenx, cutting an estimated $37.7M.
  • Rock Springs Capital Management fully exited Arcellx in Q2 2026, selling an estimated $19.5M.
  • Rock Springs Capital Management's ten largest holdings make up 44% of its $2.05B portfolio in Q2 2026.
  • Rock Springs Capital Management opened 16 new positions and closed 12 in Q2 2026.
  • Rock Springs Capital Management's portfolio value rose 21% quarter-over-quarter to $2.05B.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.